RU2394581C2 - ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ - Google Patents

ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ Download PDF

Info

Publication number
RU2394581C2
RU2394581C2 RU2007132181/15A RU2007132181A RU2394581C2 RU 2394581 C2 RU2394581 C2 RU 2394581C2 RU 2007132181/15 A RU2007132181/15 A RU 2007132181/15A RU 2007132181 A RU2007132181 A RU 2007132181A RU 2394581 C2 RU2394581 C2 RU 2394581C2
Authority
RU
Russia
Prior art keywords
day
ftd
dose
drug
days
Prior art date
Application number
RU2007132181/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2007132181A (ru
Inventor
Томохиро ЕМУРА (JP)
Томохиро ЕМУРА
Акира МИТА (JP)
Акира МИТА
Original Assignee
Тайхо Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36740357&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2394581(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US11/042,059 external-priority patent/US7799783B2/en
Application filed by Тайхо Фармасьютикал Ко., Лтд. filed Critical Тайхо Фармасьютикал Ко., Лтд.
Publication of RU2007132181A publication Critical patent/RU2007132181A/ru
Application granted granted Critical
Publication of RU2394581C2 publication Critical patent/RU2394581C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2007132181/15A 2005-01-26 2006-01-25 ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ RU2394581C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US11/042,059 US7799783B2 (en) 2005-01-26 2005-01-26 Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US11/042,059 2005-01-26
JP2005-165156 2005-06-06
JP2005165156 2005-06-06

Publications (2)

Publication Number Publication Date
RU2007132181A RU2007132181A (ru) 2009-03-10
RU2394581C2 true RU2394581C2 (ru) 2010-07-20

Family

ID=36740357

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007132181/15A RU2394581C2 (ru) 2005-01-26 2006-01-25 ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ

Country Status (21)

Country Link
EP (1) EP1849470B2 (cg-RX-API-DMAC10.html)
JP (1) JP5576591B2 (cg-RX-API-DMAC10.html)
KR (1) KR101468216B1 (cg-RX-API-DMAC10.html)
AU (1) AU2006209547C1 (cg-RX-API-DMAC10.html)
BE (1) BE2017C028I2 (cg-RX-API-DMAC10.html)
CA (1) CA2594713A1 (cg-RX-API-DMAC10.html)
CY (2) CY1119393T1 (cg-RX-API-DMAC10.html)
DK (1) DK1849470T4 (cg-RX-API-DMAC10.html)
ES (1) ES2630002T5 (cg-RX-API-DMAC10.html)
FI (1) FI1849470T4 (cg-RX-API-DMAC10.html)
FR (1) FR17C1028I2 (cg-RX-API-DMAC10.html)
HU (2) HUE033306T2 (cg-RX-API-DMAC10.html)
LT (2) LT1849470T (cg-RX-API-DMAC10.html)
LU (1) LUC00036I2 (cg-RX-API-DMAC10.html)
NL (1) NL300889I2 (cg-RX-API-DMAC10.html)
PL (1) PL1849470T5 (cg-RX-API-DMAC10.html)
PT (1) PT1849470T (cg-RX-API-DMAC10.html)
RU (1) RU2394581C2 (cg-RX-API-DMAC10.html)
SI (1) SI1849470T2 (cg-RX-API-DMAC10.html)
TW (1) TWI362265B (cg-RX-API-DMAC10.html)
WO (1) WO2006080327A1 (cg-RX-API-DMAC10.html)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9340808B2 (en) 2012-03-14 2016-05-17 Nisshin Pharma Inc. Sulfur amino acid-containing composition
RU2585528C2 (ru) * 2011-08-16 2016-05-27 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
RU2639473C2 (ru) * 2012-02-15 2017-12-21 Тайхо Фармасьютикал Ко., Лтд. Пероральная фармацевтическая композиция
RU2727598C2 (ru) * 2016-02-05 2020-07-22 Тайхо Фармасьютикал Ко., Лтд. Способ лечения больных раком с тяжелой почечной недостаточностью

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20070048228A1 (en) 2003-08-06 2007-03-01 Elisabeth Arkenau-Maric Abuse-proofed dosage form
DE10361596A1 (de) 2003-12-24 2005-09-29 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE10336400A1 (de) 2003-08-06 2005-03-24 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE102005005446A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Bruchfeste Darreichungsformen mit retardierter Freisetzung
DE102004032049A1 (de) 2004-07-01 2006-01-19 Grünenthal GmbH Gegen Missbrauch gesicherte, orale Darreichungsform
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor
DE102005005449A1 (de) 2005-02-04 2006-08-10 Grünenthal GmbH Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform
DE102007011485A1 (de) 2007-03-07 2008-09-11 Grünenthal GmbH Darreichungsform mit erschwertem Missbrauch
PL2148676T3 (pl) 2007-04-25 2016-12-30 Stosowanie sapacytabiny do leczenia choroby proliferacyjnej
MX2010008138A (es) 2008-01-25 2010-08-10 Gruenenthal Gmbh Forma de dosis farmaceutica.
TWI524904B (zh) 2008-05-09 2016-03-11 歌林達股份有限公司 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法
US20110065663A1 (en) * 2008-05-15 2011-03-17 Katholieke Universiteit Leuven, K.U. Leuven R&D Anti-cancer combination therapy
CA2765971C (en) 2009-07-22 2017-08-22 Gruenenthal Gmbh Hot-melt extruded controlled release dosage form
EP2456425B1 (en) 2009-07-22 2015-10-21 Grünenthal GmbH Tamper-resistant dosage form for oxidation-sensitive opioids
EP2611426B1 (en) 2010-09-02 2014-06-25 Grünenthal GmbH Tamper resistant dosage form comprising inorganic salt
KR20130137627A (ko) 2010-09-02 2013-12-17 그뤼넨탈 게엠베하 음이온성 중합체를 포함하는 내변조성 투여형
KR20140053159A (ko) 2011-07-29 2014-05-07 그뤼넨탈 게엠베하 즉시 약물 방출을 제공하는 탬퍼-저항성 정제
CN103857386A (zh) 2011-07-29 2014-06-11 格吕伦塔尔有限公司 提供药物立即释放的抗破碎片剂
TWI503122B (zh) 2012-02-15 2015-10-11 Taiho Pharmaceutical Co Ltd Oral administration of pharmaceutical compositions
EP2819656A1 (en) 2012-02-28 2015-01-07 Grünenthal GmbH Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer
PT2838512T (pt) 2012-04-18 2018-11-09 Gruenenthal Gmbh Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping)
US10064945B2 (en) 2012-05-11 2018-09-04 Gruenenthal Gmbh Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc
US10213432B2 (en) 2012-05-16 2019-02-26 Novartis Ag Dosage regimen for a PI-3 kinase inhibitor
KR101847252B1 (ko) 2013-03-27 2018-04-09 다이호야쿠힌고교 가부시키가이샤 이리노테칸염산염 수화물을 함유하는 항종양제
AU2014245147B2 (en) * 2013-03-27 2017-08-31 Les Laboratoires Servier Antitumor agent including low-dose irinotecan hydrochloride hydrate
KR101928618B1 (ko) 2013-05-17 2018-12-12 다이호야쿠힌고교 가부시키가이샤 Tk1 단백질의 발현이 항진된 결장직장암 환자에 대한 치료효과 예측 방법
AU2014273227B2 (en) 2013-05-29 2019-08-15 Grunenthal Gmbh Tamper-resistant dosage form containing one or more particles
AU2014273226B2 (en) 2013-05-29 2019-06-27 Grunenthal Gmbh Tamper resistant dosage form with bimodal release profile
EP3019157A1 (en) 2013-07-12 2016-05-18 Grünenthal GmbH Tamper-resistant dosage form containing ethylene-vinyl acetate polymer
EP4201424A1 (en) 2013-09-06 2023-06-28 Taiho Pharmaceutical Co., Ltd. Antitumor agent and antitumor effect enhancer
CN105934241B (zh) 2013-11-26 2020-06-05 格吕伦塔尔有限公司 通过低温研磨制备粉末状药物组合物
CN106572980A (zh) 2014-05-12 2017-04-19 格吕伦塔尔有限公司 包含他喷他多的防篡改即释胶囊制剂
MX2016015417A (es) 2014-05-26 2017-02-22 Gruenenthal Gmbh Multiparticulas protegidas contra vertido de dosis etanolico.
US20160310429A1 (en) 2015-04-24 2016-10-27 Grünenthal GmbH Tamper-resistant dosage form with immediate release and resistance against solvent extraction
AU2016319203A1 (en) 2015-09-10 2018-02-22 Grünenthal GmbH Protecting oral overdose with abuse deterrent immediate release formulations
JP6871868B2 (ja) * 2016-01-08 2021-05-19 大鵬薬品工業株式会社 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤
EP3730935A4 (en) 2017-12-22 2022-02-23 Taiho Pharmaceutical Co., Ltd. METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL
US10866219B2 (en) 2017-12-22 2020-12-15 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine- and/or tipiracil-related substance
US10816517B2 (en) 2018-01-05 2020-10-27 Taiho Pharmaceutical Co., Ltd. Method for detecting trifluridine-related substance by high-performance liquid chromatography
WO2019135405A1 (ja) 2018-01-05 2019-07-11 大鵬薬品工業株式会社 トリフルリジン由来の類縁物質の検出方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3088757B2 (ja) * 1995-03-29 2000-09-18 大鵬薬品工業株式会社 ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤
KR100284413B1 (ko) * 1996-09-24 2001-03-02 고바야시 유키오 우라실 유도체를 함유하는 암전이 억제제유도체
DK1849470T4 (en) 2005-01-26 2024-04-02 Taiho Pharmaceutical Co Ltd Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
An optimal dosing schedule for a novel combination antimetabolite, TAS-102, based on its intracellular metabolism and its incorporation into DNA. Tomohiro Emura et al. International Journal of Molecular Medicine. Vol.13, №2, 2004, pp.249-255. *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2585528C2 (ru) * 2011-08-16 2016-05-27 Тайхо Фармасьютикал Ко., Лтд. Противоопухолевый агент и способ предсказания терапевтического эффекта для пациентов с раком ободочной и прямой кишки с мутацией гена kras
US9371380B2 (en) 2011-08-16 2016-06-21 Taiho Pharmaceutical Co., Ltd. Antitumor agent and therapeutic effect prediction method for patients with KRAS-mutated colorectal cancer
RU2639473C2 (ru) * 2012-02-15 2017-12-21 Тайхо Фармасьютикал Ко., Лтд. Пероральная фармацевтическая композиция
US9340808B2 (en) 2012-03-14 2016-05-17 Nisshin Pharma Inc. Sulfur amino acid-containing composition
RU2727598C2 (ru) * 2016-02-05 2020-07-22 Тайхо Фармасьютикал Ко., Лтд. Способ лечения больных раком с тяжелой почечной недостаточностью
US10960004B2 (en) 2016-02-05 2021-03-30 Taiho Pharmaceutical Co., Ltd. Method for treating cancer patients with severe renal impairment

Also Published As

Publication number Publication date
JP5576591B2 (ja) 2014-08-20
CY2017029I2 (el) 2018-02-14
CA2594713A1 (en) 2006-08-03
FR17C1028I2 (fr) 2018-11-02
AU2006209547A1 (en) 2006-08-03
RU2007132181A (ru) 2009-03-10
AU2006209547B2 (en) 2011-05-26
DK1849470T4 (en) 2024-04-02
WO2006080327A1 (ja) 2006-08-03
PT1849470T (pt) 2017-09-22
SI1849470T2 (sl) 2024-05-31
PL1849470T5 (pl) 2024-06-10
DK1849470T3 (en) 2017-08-14
JPWO2006080327A1 (ja) 2008-06-19
ES2630002T5 (es) 2024-09-19
FR17C1028I1 (cg-RX-API-DMAC10.html) 2017-09-29
LUC00036I2 (cg-RX-API-DMAC10.html) 2017-12-01
EP1849470A1 (en) 2007-10-31
LUC00036I1 (cg-RX-API-DMAC10.html) 2017-10-02
CY1119393T1 (el) 2018-02-14
EP1849470B1 (en) 2017-06-21
CY2017029I1 (el) 2018-02-14
FI1849470T4 (fi) 2024-03-22
NL300889I1 (nl) 2017-08-14
ES2630002T3 (es) 2017-08-17
LTPA2017024I1 (lt) 2017-08-10
AU2006209547C1 (en) 2022-04-07
EP1849470B2 (en) 2024-03-20
LTC1849470I2 (lt) 2019-10-25
HUS1700032I1 (hu) 2017-09-28
KR20070104559A (ko) 2007-10-26
EP1849470A4 (en) 2010-12-08
LT1849470T (lt) 2017-07-25
PL1849470T3 (pl) 2017-11-30
NL300889I2 (nl) 2018-01-16
HUE033306T2 (hu) 2017-11-28
KR101468216B1 (ko) 2014-12-03
TWI362265B (en) 2012-04-21
TW200637562A (en) 2006-11-01
SI1849470T1 (sl) 2017-10-30
BE2017C028I2 (cg-RX-API-DMAC10.html) 2025-09-10

Similar Documents

Publication Publication Date Title
RU2394581C2 (ru) ПРОТИВОРАКОВОЕ ЛЕКАРСТВЕННОЕ СРЕДСТВО, СОДЕРЖАЩЕЕ α,α,α-ТРИФТОРТИМИДИН И ИНГИБИТОР ТИМИДИНФОСФОРИЛАЗЫ
US7799783B2 (en) Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor
US20120157472A1 (en) Method for treating colorectal cancer
WO2000056337A1 (en) Agents for relieving side effects
US20240122921A1 (en) Methods for cancer therapy
JP2023065622A (ja) 重度腎機能障害を有する癌患者に対する治療方法
JP2010106019A (ja) リマプロストを含有してなる癌化学療法に起因する末梢神経障害予防、治療および／または症状軽減剤
JP2016014051A (ja) ５−ｆｕ又はそのプロドラッグと、ｄｐｄ阻害剤との組合せに付随した神経毒性の処置
CN113893256A (zh) 化合物或其可药用盐、二聚体或三聚体在制备治疗癌症的药物中的应用
EP2268287B1 (en) Dosage regimens of an antitumor agent comprising deoxycytidine derivative
KR100740079B1 (ko) 당뇨병성 신경 장해용 의약 조성물
TWI434700B (zh) 放射線治療增強劑
JP5066737B2 (ja) シチジン誘導体を含有する持続静脈内投与用抗腫瘍剤
HK40059774A (en) Application of compound or pharmaceutically acceptable salt, dimer or trimer thereof in the preparation of medicament for treating cancer
HK1115306A (en) ANTICANCER DRUG CONTAINING α, α, α-TRIFLUOROTHYMIDINE AND THYMIDINE PHOSPHORYLASE INHIBITOR
CN109152761A (zh) 使用吲唑基苯甲酰胺衍生物治疗癌症的组合疗法
JP2003300888A (ja) 抗腫瘍効果増強剤